Biosimilars are an essential element of sustainable healthcare systems, with significant potential contribution to competitive markets. However, there are still challenges to be faced; for instance, there is a growing trend of biosimilar development targeting a limited range of biologicals .
The rate of uptake of biosimilars has accelerated as stakeholders have become increasingly comfortable with these products . However, the adoption of biosimilars is lower in regions experiencing low social and governmental trust [2, 3].
Biosimilars are now key players in the global drugs market offering potentially more affordable treatment options with similar safety and efficacy. However, there are concerns about non-medical switching practices of originator biologicals/biosimilars in different regions. A webinar was held on 20 July 2022 to discuss non-medical switching practices and to explore the importance of safeguarding the physician–patient relationship .
During the Biosimilars Medicines Conference in May 2023, Mr Aurelio Arias from IQVIA delivered a presentation about the biosimilar void in Europe. He highlighted that while the uptake of biosimilars has accelerated, there is a growing disparity in market concentration for smaller biologicals .
In Brazil, the approach of the Industrial Economic Complex of Health (Complexo Econômico-Industrial da Saúde, CEIS) has been adopted in the planning of policies related to the health economy. This involves the integration of health, industrial and innovative policies.
The biopharmaceutical industries in Latin American countries have gained significant attention in recent years, with an important growth in Argentina and Brazil where the policies implemented have emphasized collaboration between the public and private sector.
The market for copy biologicals in China has significantly grown over the past decade. The government has been actively promoting the development and use of copy biologicals as a way to improve access to affordable health care. As a result, the number of pharmaceutical companies developing copy biologicals has also increased rapidly and is expected to continue to grow in the coming years.
A report which analyses significant developments in the biosimilar space and the impacts on patient access, affordability and quality of care has been released in early 2023. The report is a product of the Patient Access and Affordability Project, a programme of Patients Rising, a non-profit organization.
The results of a study on the knowledge, perceptions and use of generic and biosimilar drugs in Latin America and the Caribbean were recently presented at an event organized by the World Bank during the workshop ‘Rethinking Pharmaceutical Policies in Latin America and the Caribbean’ held in Washington DC, USA.
US uptake of biosimilars is now beginning to rival that of Europe. This was a take home message from the June 2022 Alliance for Safe Biologic Medicines (ASBM) webinar on the successful uptake of biosimilars in Europe and the US .